Fiche du document
2023
- doi: 10.1080/2162402X.2023.2222560
- issn: 2162-4011
Ce document est lié à :
info:eu-repo/semantics/altIdentifier/doi/10.1080/2162402X.2023.2222560
Ce document est lié à :
info:eu-repo/semantics/altIdentifier/pmid/37363104
Ce document est lié à :
info:eu-repo/semantics/altIdentifier/eissn/2162-402X
Ce document est lié à :
info:eu-repo/semantics/altIdentifier/urn/urn:nbn:ch:serval-BIB_E70CC601A8007
info:eu-repo/semantics/openAccess , CC BY-NC 4.0 , https://creativecommons.org/licenses/by-nc/4.0/
Sujets proches
Radiation therapy Therapeutic immunologyCiter ce document
F. Gregucci et al., « Updates on radiotherapy-immunotherapy combinations: Proceedings of 6th annual ImmunoRad conference. », Serveur académique Lausannois, ID : 10.1080/2162402X.2023.2222560
Métriques
Partage / Export
Résumé
Focal radiation therapy (RT) has attracted considerable attention as a combinatorial partner for immunotherapy (IT), largely reflecting a well-defined, predictable safety profile and at least some potential for immunostimulation. However, only a few RT-IT combinations have been tested successfully in patients with cancer, highlighting the urgent need for an improved understanding of the interaction between RT and IT in both preclinical and clinical scenarios. Every year since 2016, ImmunoRad gathers experts working at the interface between RT and IT to provide a forum for education and discussion, with the ultimate goal of fostering progress in the field at both preclinical and clinical levels. Here, we summarize the key concepts and findings presented at the Sixth Annual ImmunoRad conference.